The Girardi Verdict: What It Means for Client Trust in PI Law

James Wong — Founder & Pharmacist, LienScripts | December 1, 2025 | 6 min read

Tom Girardi's federal conviction exposed what happens when a trusted advocate's incentives stop aligning with the client. The same misalignment can exist with any service provider in a PI case — including lien providers. Here's what plaintiff attorneys should demand.

A Verdict the PI Community Won't Forget

When federal prosecutors described Tom Girardi as a "Robin Hood in reverse — stealing from the needy to support a lavish Hollywood lifestyle," they captured something the personal injury legal community had long suspected but rarely said plainly.

Girardi wasn't convicted for incompetence. He was convicted for something more troubling: building a reputation as a champion of the injured while systematically stealing from the very clients whose settlements he was entrusted to protect. The victims included plane crash survivors, workers harmed by toxic exposure, families who had trusted him with the worst moments of their lives.

The verdict landed in an industry that has been having a quiet conversation about incentive misalignment for years. This is that conversation, made public.

[!KEY] Incentive misalignment in PI cases shows up in pricing, documentation quality, and negotiation behavior long before it becomes criminal conduct — the Girardi verdict is a useful frame for evaluating any service provider whose fees come out of the same settlement pool as the client's recovery.

The Misalignment Problem Isn't Limited to One Attorney

Girardi's case is an extreme. But the underlying dynamic — a service provider whose financial interests pull against the client's recovery — is not unique to him, and it is not unique to the attorney relationship.

Every case involves multiple providers whose fees come out of the same pool: the settlement. The attorney takes a contingency. Medical providers and lien holders take their portion. What's left goes to the client.

The question is rarely asked as directly as it should be: Is each provider priced to help the client walk away with something meaningful, or to maximize their own share?

Defense attorneys have become vocal about this. The pattern they describe — clients walking away with a fraction of a six-figure settlement after attorney fees and inflated lien balances are satisfied — is not a Girardi-level crime. But it reflects the same structural problem. When the incentives of the people around a case point away from the client's net recovery, the client loses regardless of the outcome at settlement.

What This Means for Pharmacy Liens Specifically

Pharmacy liens are a legitimate and valuable tool in personal injury cases. They allow injured clients to access necessary medications at no upfront cost, which keeps treatment continuous and supports the medical narrative in the case.

But not every pharmacy lien provider is built the same way.

The difference comes down to a single question: Does this provider price its liens with the client's net recovery in mind?

A provider that inflates medication charges beyond any defensible clinical rationale, uses boilerplate documentation that can't withstand scrutiny, or holds firm on every dollar regardless of merit at negotiation — that provider is not aligned with the client. It is aligned with its own revenue.

A provider that is transparent, clinically supported, and willing to engage reasonably at negotiation is one whose incentives actually track the client's interests. That alignment is what makes a lien worth recommending.

Three Questions to Ask Any Lien Provider Before Recommending Them

1. Is there a licensed pharmacist behind the clinical documentation?

Dispensing records are transaction records. They show what was prescribed and when. Clinical documentation requires a pharmacist — someone with a professional credential who can explain why each medication was clinically appropriate for this patient's specific injury profile.

A provider without pharmacist oversight has no one to stand behind the documentation when it's challenged. And it will be challenged.

2. Does the provider engage reasonably in lien negotiations?

A provider that refuses to reduce on any line item regardless of the clinical record is not your partner. They are a creditor.

The right partner can distinguish between medications that are fully supported and line items where the clinical case is genuinely weaker. They participate in the resolution process rather than obstruct it. That behavior is what keeps cases moving and clients whole.

[!TIP] Ask any lien provider three questions before recommending them: Is there a licensed pharmacist behind the documentation? Do they engage reasonably in negotiations? Are the non-recourse terms explicit and unconditional in writing?

3. Are the non-recourse terms explicit and unconditional?

If there is no recovery, the lien must be waived — in writing, without conditions. Not "subject to review," not "at our discretion." The non-recourse protection should be explicit in the agreement.

This is the foundation on which you can recommend a lien to your client with confidence. A genuinely non-recourse lien is a risk-free option. Anything less is not.

The Lesson That Extends Beyond Girardi

The Girardi verdict will be discussed in law schools, bar association meetings, and legal ethics seminars for years. The obvious lesson is about attorney misconduct and client fund management.

The less obvious lesson is about incentive structure. Girardi did not start as a thief. He built a legitimate reputation over decades. What changed — according to prosecutors — was that his personal financial obligations grew until maintaining his lifestyle required redirecting client funds. The incentives flipped. The client's interest became an obstacle.

This is a useful frame for evaluating any service provider in the PI ecosystem. Not because they are likely to commit wire fraud, but because incentive misalignment shows up long before criminal behavior. It shows up in pricing. It shows up in documentation quality. It shows up in how a provider behaves at the negotiation table.

[!KEY] Incentive alignment in a lien provider shows up most clearly at the negotiation table — a provider that participates reasonably in lien reduction when the clinical case warrants it is aligned with the client's recovery; one that refuses to engage regardless of merit is a creditor, not a partner.

[!KEY] Before recommending any pharmacy lien provider, confirm three things in writing: licensed pharmacist oversight behind the documentation, explicit non-recourse terms, and a track record of good-faith lien negotiations — these three criteria separate aligned providers from adversarial ones.

Attorneys who ask the hard questions before recommending any provider — including pharmacy lien companies — are doing exactly what they should.

Want to understand how LienScripts approaches lien pricing and documentation? Contact us or request a MERIT report sample to see what our clinical documentation looks like.

Related Reading

• How to Evaluate a Pharmacy Lien Provider Before Recommending One
• Can You Recommend a Pharmacy Lien Provider Without Creating Liability?
• Why Some Pharmacy Liens Face More Challenges at Settlement